[HTML][HTML] Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillation
T Lanitis, T Kongnakorn, L Jacobson, A De Geer - Thrombosis research, 2014 - Elsevier
Introduction Atrial fibrillation (AF), one of the major risk factors for stroke, imposing a
substantial burden to the Swedish health care system. Apixaban has demonstrated …
substantial burden to the Swedish health care system. Apixaban has demonstrated …
Cost-effectiveness of apixaban vs. current standard of care for stroke prevention in patients with atrial fibrillation
P Dorian, T Kongnakorn, H Phatak… - European heart …, 2014 - academic.oup.com
Aims Warfarin, a vitamin K antagonist (VKA), has been the standard of care for stroke
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …
prevention in patients with atrial fibrillation (AF). Aspirin is recommended for low-risk patients …
A systematic literature review on the cost-effectiveness of apixaban for stroke prevention in non-valvular atrial fibrillation
C Pinyol, JM Cepeda, I Roldan, V Roldan… - Cardiology and …, 2016 - Springer
Introduction Economic evaluations are becoming increasingly important due to limitations in
economic resources, the expense of many new treatments, the need to allocate health …
economic resources, the expense of many new treatments, the need to allocate health …
Cost effectiveness of apixaban versus warfarin or aspirin for stroke prevention in patients with atrial fibrillation: a Greek perspective
K Athanasakis, N Boubouchairopoulou… - American Journal of …, 2017 - Springer
Background Strokes attributed to atrial fibrillation (AF) represent a major cause of adult
disability and a great burden to society and healthcare systems. Objectives Our objective …
disability and a great burden to society and healthcare systems. Objectives Our objective …
Cost-effectiveness analysis of apixaban compared to other direct oral anticoagulants for prevention of stroke in Austrian atrial fibrillation patients
E Walter, M Voit, G Eichhober - Expert Review of …, 2021 - Taylor & Francis
Objectives Several direct oral anticoagulants (DOACs) have been approved by the
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …
European Medicines Agency since 2008. The aim of the present cost-effectiveness-analysis …
Cost-effectiveness of apixaban compared to warfarin in the management of atrial fibrillation in Australia
Objective To determine the cost-effectiveness of apixaban versus warfarin in patients with
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …
atrial fibrillation (AF) with a moderate to severe risk of stroke, from an Australian government …
Cost-effectiveness of apixaban compared with warfarin for stroke prevention in atrial fibrillation
S Lee, R Mullin, J Blazawski, CI Coleman - 2012 - journals.plos.org
Background Apixaban was shown to be superior to adjusted-dose warfarin in preventing
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …
stroke or systemic embolism in patients with atrial fibrillation (AF) and at least one additional …
Cost–effectiveness of apixaban and warfarin in the prevention of thromboembolic complications among atrial fibrillation patients
T Hallinen, EJ Soini, M Linna, SI Saarni - Springerplus, 2016 - Springer
Background To reduce the risk of thromboembolic complications, clinical guidelines
recommend anticoagulation treatment for almost all atrial fibrillation (AF) patients. Although …
recommend anticoagulation treatment for almost all atrial fibrillation (AF) patients. Although …
Cost-effectiveness of apixaban versus other direct oral anticoagulants and warfarin in the prevention of thromboembolic complications among Finnish patients with …
T Hallinen, E Soini, C Asseburg, M Linna… - ClinicoEconomics …, 2021 - Taylor & Francis
Purpose Direct oral anticoagulant (DOAC) use for the prevention of thromboembolic
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …
complications in patients with non-valvular atrial fibrillation (AF) has increased steadily in …
Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in Belgium
T Kongnakorn, T Lanitis, L Annemans, V Thijs… - Clinical drug …, 2014 - Springer
Abstract Background and Objective Evidence indicates that vitamin K antagonists (VKAs)
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …
and oral anticoagulant therapy are under-utilised for stroke prevention in patients with non …